Abstract
Objective: To determine the association of anti-Ro antibody with the clinical features and serology in systemic lupus erythematosus (SLE) patients. Methods: This retrospective observational study enrolled 158 SLE patients at the Rheumatology Department, Fauji Foundation Hospital, from May 1 to October 31, 2023. Demographic and clinical data were collected. Patients were stratified by anti-Ro (positive vs. negative), concomitant anti-La (anti-Ro[ ]/anti-La[ ], anti-Ro[ ]/anti-La[ ], anti-Ro[ ]/anti-La[ ], and anti-Ro[ ]/anti-La[ ]), and anti-nuclear antibody (ANA) status (positive vs. negative). Mann-Whitney U and Chi-square tests were employed for comparisons, with statistical significance set at p<0.05. Results: The study population consisted mainly of females (98.7%), with a median age of 30 years. Anti-Ro[ ] patients (46.8%) exhibited higher discoid rash (16.2% vs. 6%, p [ ] 0.04), sicca symptoms (52.7% vs. 31%, p [ ] 0.005), and anemia (71.6% vs. 56%, p [ ] 0.04). No significant differences were observed in nephritis (29.7% vs. 34.5%, p [ ] 0.52) or neurological disease (9.5% vs. 11.9%, p [ ] 0.69) between the two groups. The anti-Ro[ ]/anti-La[ ] group had higher myositis (20.6%), sicca symptoms (55.9%), and fever (70.6%) compared to other groups. The ANA[ ]/anti-Ro[ ] group (48.6%) had significant association with sicca symptoms (50.7%) and fever (64.2%). Conclusion: Anti-Ro[ ] SLE in South Asians is associated with sicca symptoms, anemia, fever, and myositis—findings critical for tailored management. Co-positivity with anti-La amplifies risks, warranting vigilant monitoring.

This publication has 17 references indexed in Scilit: